Procedure for Requesting Biological Samples and Data from the Accelerated Cure Project MS Repository



Similar documents
I. INTRODUCTION DEFINITIONS AND GENERAL PRINCIPLE

J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S

IRB REVIEW OF USE OF RESEARCH REPOSITORIES

J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H

Innovation Platform: Sudden Cardiac Death

Application for an Off-Site Tissue Banking Waiver at a Non-Profit or Academic Institution

IRB RESEARCH REPOSITORY COMPLIANCE PROGRAM. Susan Burner Bankowski, MS, JD Chair, OHSU IRB

Research Involving Human Biological Materials: Ethical Issues and Policy Guidance Executive Summary

AUBAGIO (teriflunomide) oral tablet

STANDARD OPERATING POLICY AND PROCEDURE

2.1 Who first described NMO?

LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH

Clinically isolated syndrome (CIS)

How To Change Medicine

Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis

Multiple Myeloma Research Foundation Senior Research Award. Program Guidelines

7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology)

Clinical Trials: Questions and Answers

Disease Modifying Therapies for MS

Pl"OtocolDirector: Iris Schrijver _ IRB Approval Date: _June IRE Expiration Date: June 19, 2007 _ STANFORD SAMPLE CONSENT FORM

10/31/2014. Much is unknown. What is npod? THE JDRF Network for the Pancreatic Organ Donor with Diabetes (npod):

BIOBANK QUALITY. Office:

Human Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT

Centre for Biomarker Research in Medicine. COMET Competence Centre for Excellent Technologies

Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff

Wilson Disease Research and Care. Looking Forward Ann Arbor, Michigan September 6, 2014 Fred Askari MD, PhD

THE LEE SCHIPPER MEMORIAL SCHOLARSHIP FOR SUSTAINABLE TRANSPORT AND ENERGY EFFICIENCY Contact:

Roche Position on Human Stem Cells

Memorandum. Factual Background

RESEARCH INVOLVING DATA AND/OR BIOLOGICAL SPECIMENS

USMLE Step 1. Content Description and General Information

ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES

2 Year ( ) CLL/SLL Research Initiative CLL/SLL Collaborative Grant

INVESTIGATOR-INITIATED RESEARCH GRANTS

FastTest. You ve read the book now test yourself

Department of Environmental Science, Policy, and Geography Bylaws. Article I. The Department of Environmental Science, Policy and Geography

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences

OHTAC Recommendation

Clinically Actionable Biomarkers in Rheumatoid Arthritis

Multiple Myeloma Research Foundation Research Fellow Award. Program Guidelines

MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA

Focus Biobank Inflammatory Bowel Disease

Course Descriptions. I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students)

50-State Survey of Laws Regulating the Collection, Storage, and Use of Human Tissue Specimens and Associated Data for Research

Guide to Completing a Graduate Degree

Press Release Description Thread

Regulatory Issues in Genetic Testing and Targeted Drug Development

Movember Clinical Trial Award (CTA)

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005

Leukemia Drug Pathway Analyzer

MEDICAL LABORATORY TECHNOLOGIST COMPETENCY PROFILE

Certified Employee Peer Assistance and Review (PAR) Program Washoe County School District

Guidance for Clinical Investigators, Sponsors, and IRBs

NC SBI QUALITY ASSURANCE PROGRAM

E Lighting Group Holdings Limited 壹 照 明 集 團 控 股 有 限 公 司 (incorporated in the Cayman Islands with limited liability) Stock Code : 8222

Clinical Trials of Disease Modifying Treatments

Global Multiple Sclerosis Epidemiology and Patient Flow Analysis

POLICY AND PROCEDURES OFFICE OF NEW DRUGS. Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics.

Disease Modifying Therapies for MS

TAKING PART IN CANCER TREATMENT RESEARCH STUDIES

Global Multiple Myeloma Epidemiology and Patient Flow Analysis

Original Policy Date

Global Haemophilia Epidemiology and Patient Flow Analysis

Mariusz Stasiołek Neurology Department Polish Mother s Memorial Hospital Research Institute, Lodz

Review of diabetes care in London Health and Environment Committee

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

targeted therapy a guide for the patient

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

FDA Regulation of Whole Slide Imaging (WSI) Devices: Current Thoughts

Application for Research

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center

INFORMATION FOR GRADUATE STUDENTS IN BIOCHEMISTRY. Department of Chemistry and Biochemistry Utah State University, Logan, Utah

Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health

RUCDR Infinite Biologics Cell Culture and Stem Cell Center

Clinical Trials and Screening: What You Need to Know

Transcription:

Procedure for Requesting Biological Samples and Data from the Accelerated Cure Project MS Repository March 2009 The Accelerated Cure Project Blood, Tissue and Data Bank solicits proposals requesting biological samples from investigators studying the causes or triggers of MS and related demyelinating diseases. To request specimens, please follow these procedures: 1. Submit a written proposal to the Accelerated Cure Project using the attached form. This proposal will contain information about your research plan as well as the number and type of specimens required. The proposal must include a description of your plans for contributing the data generated from use of the specimens back to Accelerated Cure Project for incorporation into the sample database. These plans must include type of data to be contributed, expected timing of the contribution, and quality control mechanisms to be applied to the data before contribution. Proposals are accepted and reviewed year round. 2. Your proposal will be initially reviewed by Accelerated Cure Project staff for completeness, alignment with the purpose of the repository, and our ability to fulfill the request. You will be notified if any problems are found and given the opportunity to make appropriate changes. 3. After the preliminary review is complete, your proposal will be reviewed by the Accelerated Cure Project Repository Oversight Committee, composed of representatives from Accelerated Cure Project, the Transverse Myelitis Association, the collection sites, and others. This committee will make a recommendation regarding whether to grant your request. Factors influencing this recommendation include: Potential benefit to people with MS and/or related demyelinating diseases Scientific merit of the application Experience of the investigator Adequacy of plans for contributing data generated through use of the specimens Statistical validity of the study Use of techniques designed to minimize the specimen volume required, if nonrenewable specimens are requested Scale of experiment (data on more samples is preferred to fewer, inclusion of multiple diseases is preferred to a single disease) 4. Accelerated Cure Project will make the final decision on providing the samples and associated data. If Accelerated Cure Project cannot meet your needs, we will attempt to identify an appropriate alternative resource. If your proposal is approved, you will be sent a letter of approval with a commitment from Accelerated Cure Project to provide the necessary specimens along with a materials transfer agreement. If your proposal is not accepted, you will be sent a letter stating the concerns that prevented your proposal from being approved, and invited to resolve any remaining scientific issues so that the proposal may be resubmitted.

Request for Samples from the Accelerated Cure Project MS Repository Use as much space as you need to answer the questions. Date: Name of investigator: Investigator's institution: Address: Phone number: Email address: Fax number: Description of research to be performed and its benefit to people with MS or other demyelinating diseases, written in language understandable by non-researchers. Explain how the information to be generated by your research will potentially improve the lives of people with MS, TM, NMO, ADEM, ON, or a clinically isolated syndrome. For example, if your research could help to treat, cure, or diagnose these diseases, describe in simple language how the results would facilitate these outcomes.

Description of samples requested: Type(s) of sample (DNA, serum, etc.) needed Number and type(s) of subjects (MS, CIS, TM, ADEM, ON, NMO, controls) including special requests such as RRMS not on disease-modifying therapy or Controls both parents Any requirements concerning blood relationships between subjects (such as only one case per family, or only controls who are not genetically related to cases) Quantity/volume of each type of sample needed Contact Accelerated Cure Project at 781-487-0032 or sloud@acceleratedcure.org if you have questions about sample availability. Detailed description of research to be performed using the samples: Description of techniques to be used in performing the experiment Description of results that are expected to be generated through this research Analysis of the statistical power of your proposed experiment Quality assurance/quality control processes to be followed What important questions regarding the etiology, pathogenesis, biomarkers, or diagnosis of MS and/or related demyelinating diseases will your study help to answer?

Description of data elements from case report form (CRF) or previously returned research data needed to accompany samples: Note: Our case report form can be downloaded here: http://www.acceleratedcure.org/repository/downloads/acp_crf.pdf Description of data to be returned to the Repository database upon completion of your experiment: Specific data elements that will be provided for each sample analyzed Data QA/QC processes to be followed Note that a grace period will be allowed between completion of the experiment and submission of your data to the repository database to allow for publication and securing of IP rights. Has your proposed study been approved by an IRB? If not, please describe your plans for obtaining IRB approval: Have you obtained full financial support for your study, including support for sample/data acquisition costs? Our pricing policy can be found here: http://www.acceleratedcure.org/repository/downloads/acp_cost_recovery_policy.pdf

If not, please explain: How did you hear about the Accelerated Cure Project repository? Please direct all proposals and questions about the review process, and submit completed proposals to: Hollie Schmidt (hollie@acceleratedcure.org, 1-781-487-0099)